Approved by the US Food and Drug Administration for the treatment of refractory gout, pegloticase, in combination with immunomodulatory agents, is an area of gout treatment that has shown much promise.  Our featured guest on this episode is Brian LaMoreaux, MD, MS, an investigator on many gout studies, who provides an overview of the notable research in pegloticase treatment in gout, as presented at the American College of Rheumatology (ACR) 2020 annual meeting.